South Africa · Delayed Price · Currency is ZAR · Price in ZAc Aspen Pharmacare Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Revenue declined 4% year-over-year to ZAR 21 billion, driven by manufacturing losses, while commercial pharma delivered double-digit EBITDA growth. APAC divestment will eliminate debt and support future share buybacks, with guidance for strong H2 and double-digit normalized HEPS growth.
-
Divestment of the APAC business for ZAR 26.5 billion will significantly reduce debt and enhance balance sheet flexibility, with proceeds used to drive organic growth in pharma and manufacturing. GLP-1s and contract manufacturing are key future growth drivers.
Fiscal Year 2025
-
Despite macroeconomic turbulence and a major contract loss, commercial pharma delivered strong growth, especially in Africa and Latin America. EBITDA and earnings were impacted by FX and tax changes, but cash conversion was robust. Outlook is positive, with focus on cost control, manufacturing turnaround, and GLP-1 opportunities.
-
Strong H1 2025 results with double-digit CER growth in revenue and EBITDA, driven by robust commercial pharma and manufacturing performance. Strategic progress in GLP-1, insulin, and vaccine manufacturing positions the business for sustained growth, despite currency and tax headwinds.
Fiscal Year 2024
-
Revenue grew 10% year-over-year, driven by manufacturing and commercial pharma, with EBITDA and HEPS up 17% in H2. Strategic focus on GLP-1s and sterile manufacturing positions for strong future growth, while risks from regulatory timelines and pricing remain.